white open door inside empty room with view to green field and cloud sky background

The pharmaceutical industry is facing a real challenge. R&D efficiency declines fairly steadily, late stage attrition is high and drug development is costly. The biotech’s profitability is also under pressure as R&D budgets become increasingly strained. A possible solution known as “quick-kill strategy” consists in reducing R&D costs by terminating failing projects earlier in the development process. Although stopping a project is inevitable, the way how termination is conducted may have a profound and long lasting impact on your organization.

Conducting periodic reviews of the project

The most effective way to limit the negative impact of a failing project is to know not only when to cancel it but also how to cancel it. Projects have a life cycle. They are born from an idea. Through this process, the project manager should continually check the critical success factors to ensure the project is still viable. He is entrusted with the task of conducting periodic reviews of the project and is responsible for closely monitoring the project progress throughout an efficient data management. Biocorpora is a central repository in which biological data is integrated for both operational and strategic decision-making. Biocorpora tracks all the information generated during one or several projects. In one click, you have access to a complete review for a selected set of compounds. Biocorpora builds automatically report tables or specific reports to compare datasets and helps in decision-making process.

Advancing back-up compounds: when one door closes, another door opens

Organizing a project’s termination process is especially important when a project has failed. An objective review of the project’s successes and shortcomings can provide project manager recommendations for similar projects in the future. Biocorpora enables you to keep in mind all raw data files and study reports generated in a project and provides the ability to re-use data. Because only 20% of compounds that advance to clinical trials reach the market, Biocorpora enables fallback plans as an alternative to canceling projects and writing off significant investments. Biocorpora designates and advances backup compounds based on similar or different chemical scaffolds as the lead.

Diverting resources for potentially successful projects

A fundamental premise for successful quick-still strategy is that when a project is terminated, there are others waiting to enter the portfolio (Nature Review October 2015-Why is so hard to terminate failing projects in RD). Biocorpora can manage several projects in one single data warehouse. Authorized Biocorpora users can access all the projects or only the project they are involved in.

Learn more about Biocorpora, contact us.